Hepatitis C Drugs May Need Longer Follow-Up, US FDA Guidance Says
Executive Summary
Final guidance on developing direct-acting antivirals for hepatitis C virus clarifies recommended trial population and trial design for combination drugs.
You may also be interested in...
FDA Is Raising The Bar On Hepatitis C Approvals
New revised draft guidance on HCV drug development recommends that interferon-free regimens, which have become the standard of care, be studied against a direct-acting antiviral comparator.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.